LNTH
LNTH clinical trials: Lantheus Holdings, Inc.
Every trial on ClinicalTrials.gov where Lantheus Holdings, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 17
- As lead sponsor
- 4
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
LNTH on the catalyst calendar · LNTH registry changes
- Primary completion Oct 7, 2026ActualPhase 1NCT06790394Test-retest Study With [18F]FBB in Cardiac AmyloidosisLantheus Germany GmbH · Cardiac AmyloidosisCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2028Sponsor estimatePhase 3NCT05641688[18F]PI-2620 Phase 3 Histopathological StudyLantheus Biosciences Ltd. · Alzheimer DiseaseRecruitingLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2026ActualPhase 3NCT05184088Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisLantheus Germany GmbH · Cardiac AmyloidosisCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2011ActualPhase 1NCT01103310Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualPhase 1NCT01089998PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualPhase 3NCT01020838Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to HistopathologyLantheus Biosciences Ltd. · Alzheimer DiseaseCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2010ActualPhase 2NCT00750282Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable...Lantheus Biosciences Ltd. · Alzheimer DiseaseCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2016ActualPhase 4NCT02681172Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With ADLantheus Biosciences Ltd. · Alzheimer's Disease (AD)CompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1/Phase 2NCT02483884PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerLantheus Biosciences Ltd. · Prostate CancerTerminatedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2016ActualPhase 1NCT02370563PET Imaging of Intracranial Cancers With 18F-FSPGLantheus Biosciences Ltd. · Brain CancerTerminatedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01186601Exploration of Tumor Accumulation of BAY94-9392 in Patients With CancerLantheus Biosciences Ltd. · NeoplasmsCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 1NCT01138111Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) PatientsLantheus Biosciences Ltd. · Alzheimer DiseaseCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 2NCT00928304Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.Lantheus Biosciences Ltd. · Down SyndromeCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2011ActualPhase 1NCT01297088PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01287845PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2011ActualPhase 1NCT01205321PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2011ActualPhase 1NCT01153607Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation...Lantheus Biosciences Ltd. · Diagnostic ImagingCompletedLNTHLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2027Sponsor estimatePhase 2NCT03976843Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate CancerNational Cancer Institute (NCI) · Prostate CancerActive, not recruitingLNTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2031Sponsor estimatePhase 2NCT07364071Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate CancerUniversity of California, San Diego · Prostate AdenocarcinomaRecruitingLNTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2016ActualPhase 1NCT02469376Evaluation of a New Imagingtechnologie for ThrombosisUniversity of Zurich · Abdominal Aortic AneurysmTerminatedLNTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualEarly Phase 1NCT02531360Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesMolecular NeuroImaging · Alzheimer's Disease (AD)CompletedLNTHCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner